Aytu BioPharma, Inc. (AYTU)
USD 1.03
(0.98%)
USD 1.03
(0.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -4.87 Million USD | 26.37% |
| 2023 | -6.62 Million USD | -465.19% |
| 2022 | -1.17 Million USD | 94.5% |
| 2021 | -21.3 Million USD | 53.76% |
| 2020 | -46.07 Million USD | -317.18% |
| 2019 | -11.04 Million USD | -57.49% |
| 2018 | -7.01 Million USD | -774.02% |
| 2017 | -802.32 Thousand USD | 90.04% |
| 2016 | -8.05 Million USD | -9.54% |
| 2015 | -7.35 Million USD | -475.09% |
| 2014 | 1.96 Million USD | 1907.57% |
| 2013 | 97.64 Thousand USD | 43.72% |
| 2012 | 67.94 Thousand USD | 40.65% |
| 2011 | 48.3 Thousand USD | -36.48% |
| 2010 | 76.05 Thousand USD | 85.48% |
| 2009 | 41 Thousand USD | 291.55% |
| 2008 | 10.47 Thousand USD | -5.16% |
| 2007 | 11.04 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -4.87 Million USD | -141.02% |
| 2024 Q3 | 11.89 Million USD | 441.08% |
| 2024 Q2 | -3.48 Million USD | 9.34% |
| 2024 Q1 | -3.84 Million USD | 41.95% |
| 2023 Q3 | 5.91 Million USD | 131.87% |
| 2023 Q2 | 2.55 Million USD | 305.89% |
| 2023 Q4 | -6.62 Million USD | -211.99% |
| 2023 Q1 | -1.23 Million USD | -5.72% |
| 2023 FY | -6.62 Million USD | -465.19% |
| 2022 Q1 | -15.28 Million USD | 28.25% |
| 2022 FY | -1.17 Million USD | 94.5% |
| 2022 Q4 | -1.17 Million USD | 81.55% |
| 2022 Q3 | -6.35 Million USD | 17.58% |
| 2022 Q2 | -7.7 Million USD | 49.57% |
| 2021 Q4 | -21.3 Million USD | -8.12% |
| 2021 FY | -21.3 Million USD | 53.76% |
| 2021 Q1 | -35.99 Million USD | 21.88% |
| 2021 Q2 | -60.96 Million USD | -69.39% |
| 2021 Q3 | -19.7 Million USD | 67.68% |
| 2020 Q2 | -4.88 Million USD | 26.22% |
| 2020 Q3 | -57.55 Million USD | -1078.18% |
| 2020 FY | -46.07 Million USD | -317.18% |
| 2020 Q4 | -46.07 Million USD | 19.95% |
| 2020 Q1 | -6.62 Million USD | 40.05% |
| 2019 Q1 | -3.96 Million USD | 43.46% |
| 2019 FY | -11.04 Million USD | -57.49% |
| 2019 Q3 | -9.51 Million USD | 25.5% |
| 2019 Q4 | -11.04 Million USD | -16.1% |
| 2019 Q2 | -12.76 Million USD | -222.06% |
| 2018 FY | -7.01 Million USD | -774.02% |
| 2018 Q4 | -7.01 Million USD | 41.59% |
| 2018 Q2 | -3.9 Million USD | 44.34% |
| 2018 Q1 | -7.02 Million USD | -775.14% |
| 2018 Q3 | -12 Million USD | -207.2% |
| 2017 Q3 | -3.47 Million USD | 33.65% |
| 2017 Q2 | -5.23 Million USD | -90.25% |
| 2017 FY | -802.32 Thousand USD | 90.04% |
| 2017 Q1 | -2.74 Million USD | 65.87% |
| 2017 Q4 | -802.32 Thousand USD | 76.88% |
| 2016 Q2 | -6.03 Million USD | -15.15% |
| 2016 Q4 | -8.05 Million USD | 6.95% |
| 2016 FY | -8.05 Million USD | -9.54% |
| 2016 Q1 | -5.24 Million USD | 28.69% |
| 2016 Q3 | -8.65 Million USD | -43.36% |
| 2015 Q4 | -7.35 Million USD | -212.97% |
| 2015 FY | -7.35 Million USD | -475.09% |
| 2015 Q3 | 6.5 Million USD | 28202.81% |
| 2015 Q2 | 22.99 Thousand USD | -19.79% |
| 2015 Q1 | 28.67 Thousand USD | 46.6% |
| 2014 Q3 | 112.84 Thousand USD | 7.98% |
| 2014 Q4 | 19.55 Thousand USD | -82.67% |
| 2014 Q1 | 97.64 Thousand USD | 2.34% |
| 2014 FY | 1.96 Million USD | 1907.57% |
| 2014 Q2 | 104.5 Thousand USD | 7.02% |
| 2013 Q3 | 80.14 Thousand USD | -3.01% |
| 2013 Q4 | 95.41 Thousand USD | 19.06% |
| 2013 FY | 97.64 Thousand USD | 43.72% |
| 2013 Q1 | 67.94 Thousand USD | 22.69% |
| 2013 Q2 | 82.62 Thousand USD | 21.61% |
| 2012 Q3 | -848.00 USD | -101.45% |
| 2012 Q2 | 58.28 Thousand USD | 20.65% |
| 2012 FY | 67.94 Thousand USD | 40.65% |
| 2012 Q1 | 48.3 Thousand USD | -6.22% |
| 2012 Q4 | 55.38 Thousand USD | 6630.66% |
| 2011 Q4 | 51.5 Thousand USD | 921.52% |
| 2011 FY | 48.3 Thousand USD | -36.48% |
| 2011 Q3 | -6270.00 USD | -112.77% |
| 2011 Q2 | 49.08 Thousand USD | -35.46% |
| 2011 Q1 | 76.05 Thousand USD | 5.78% |
| 2010 Q2 | 56.55 Thousand USD | 37.93% |
| 2010 Q3 | -451.00 USD | -100.8% |
| 2010 FY | 76.05 Thousand USD | 85.48% |
| 2010 Q4 | 71.9 Thousand USD | 16042.35% |
| 2010 Q1 | 41 Thousand USD | -13.15% |
| 2009 Q1 | 10.47 Thousand USD | 271.17% |
| 2009 Q4 | 47.21 Thousand USD | 564.3% |
| 2009 Q3 | -10.16 Thousand USD | -132.45% |
| 2009 Q2 | 31.33 Thousand USD | 199.19% |
| 2009 FY | 41 Thousand USD | 291.55% |
| 2008 Q1 | 11.04 Thousand USD | 123.88% |
| 2008 FY | 10.47 Thousand USD | -5.16% |
| 2008 Q4 | -6118.00 USD | 74.11% |
| 2008 Q2 | -34.69 Thousand USD | -414.21% |
| 2008 Q3 | -23.63 Thousand USD | 31.89% |
| 2007 Q4 | 4932.00 USD | 0.0% |
| 2007 FY | 11.04 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 364.806% |
| Alpha Teknova, Inc. | 1.97 Million USD | 347.062% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 105.177% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 106.507% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.12% |
| Cosmos Health Inc. | 8.59 Million USD | 156.77% |
| Journey Medical Corporation | -9.7 Million USD | 49.768% |
| Embecta Corp. | 1.31 Billion USD | 100.372% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.063% |
| Dynavax Technologies Corporation | 106.63 Million USD | 104.574% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 96.272% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.127% |
| PainReform Ltd. | -7.95 Million USD | 38.654% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 68.806% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 68.806% |
| SCYNEXIS, Inc. | -19.35 Million USD | 74.796% |
| Safety Shot Inc | -2.28 Million USD | -113.494% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 48.281% |
| Procaps Group, S.A. | 242.93 Million USD | 102.008% |
| Theratechnologies Inc. | 24.87 Million USD | 119.609% |
| Harrow Health, Inc. | 116.41 Million USD | 104.189% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -93.532% |
| Biofrontera Inc. | 4.05 Million USD | 220.242% |
| DURECT Corporation | -7.65 Million USD | 36.282% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 85.454% |
| Cronos Group Inc. | -663.32 Million USD | 99.265% |
| OptiNose, Inc. | 58.06 Million USD | 108.399% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.782% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 66.532% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 5.959% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 132.485% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 23.313% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 4663.958% |
| Radius Health, Inc. | 359.28 Million USD | 101.357% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 2573.011% |
| ProPhase Labs, Inc. | 19.23 Million USD | 125.36% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.072% |
| Procaps Group S.A. | 242.93 Million USD | 102.008% |
| Alvotech | 1.06 Billion USD | 100.458% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 232.599% |
| Viatris Inc. | 17.13 Billion USD | 100.028% |
| Rockwell Medical, Inc. | 4.45 Million USD | 209.448% |
| SIGA Technologies, Inc. | -148.68 Million USD | 96.72% |
| Tilray Brands, Inc. | 158.97 Million USD | 103.068% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 104.001% |
| Shineco, Inc. | 29.29 Million USD | 116.651% |
| PetIQ, Inc. | 351.93 Million USD | 101.386% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -68.09% |
| Incannex Healthcare Limited | -5.48 Million USD | 11.085% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 102.751% |
| Alimera Sciences, Inc. | 55.3 Million USD | 108.818% |
| Silver Spike Investment Corp. | -32.61 Million USD | 85.045% |
| Assertio Holdings, Inc. | -32.52 Million USD | 85.007% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -227.596% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 3.624% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -1.309% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 40.622% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 215.651% |
| Hempacco Co., Inc. | 13.61 Million USD | 135.822% |
| Talphera, Inc. | -5.72 Million USD | 14.753% |
| Alvotech | 1.06 Billion USD | 100.458% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 168.258% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 94.957% |
| Currenc Group, Inc. | -16.57 Million USD | 70.573% |
| Kamada Ltd. | -46.43 Million USD | 89.496% |
| Indivior PLC | -33.95 Million USD | 85.636% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 1971.637% |
| Flora Growth Corp. | -713 Thousand USD | -584.011% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 40.622% |
| Evolus, Inc. | 63.7 Million USD | 107.655% |
| HUTCHMED (China) Limited | -197.45 Million USD | 97.53% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.018% |
| Akanda Corp. | 3.9 Million USD | 224.894% |